Zevra Therapeutics (ZVRA) Total Current Liabilities (2014 - 2026)

Zevra Therapeutics' Total Current Liabilities history runs 13 years deep, the most recent figure standing at $47.0 million for Q1 2026.

• Quarterly Total Current Liabilities rose 74.33% year-over-year to $47.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.0 million (up 74.33% YoY) and the FY2025 annual result came in at $39.3 million, up 15.3% from the prior year.
• Total Current Liabilities was $47.0 million for Q1 2026 at Zevra Therapeutics, up from $39.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $73.7 million in Q4 2023 and bottomed at $7.2 million in Q2 2022.
• A 5-year average of $29.1 million and a median of $28.8 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities surged 513.16% — and 2024, when it slumped 53.79%.
• Zevra Therapeutics' Total Current Liabilities stood at $12.0 million in 2022, then jumped by 513.16% to $73.7 million in 2023, then slumped by 53.79% to $34.1 million in 2024, then rose by 15.3% to $39.3 million in 2025, then grew by 19.73% to $47.0 million in 2026.
• Business Quant data shows ZVRA's Total Current Liabilities at $47.0 million in Q1 2026, $39.3 million in Q4 2025, and $26.1 million in Q3 2025.